Related Experiment Videos
Carnitine deficiency associated with anticonvulsant therapy.
S Rodriguez-Segade1, C A de la Peña, J C Tutor
1Department of Biochemistry (Faculty of Pharmacy), University of Santiago de Compostela, Spain.
Summary
Valproic acid and other anticonvulsants can cause carnitine deficiency in epilepsy patients. This deficiency impacts a significant percentage of individuals undergoing treatment, with unknown consequences for non-valproate drugs.
Area of Science:
- Neurology
- Clinical Pharmacology
- Biochemistry
Background:
- Valproic acid (VPA) is a widely used antiepileptic drug (AED) known to induce carnitine deficiency.
- The prevalence and impact of carnitine deficiency associated with other AEDs are less understood.
Purpose of the Study:
- To investigate the association between valproate and non-valproate AEDs and carnitine deficiency.
- To compare the rates of carnitine deficiency in patients treated with valproate versus other AEDs.
Main Methods:
- Serum free carnitine and acylcarnitine levels were measured in epileptic patients.
- Patients were categorized based on their AED treatment: valproate, other AEDs, or no AEDs (controls).
Main Results:
- A high rate (76.5%) of serum free carnitine deficiency was observed in patients treated with valproate.
- Patients on valproate showed significantly higher acylcarnitine levels compared to controls (p < 0.01).
- A carnitine deficiency rate of 21.5% was found in patients treated with AEDs other than valproate.
Conclusions:
- Valproate therapy is strongly associated with carnitine deficiency in epileptic patients.
- A notable percentage of epileptic patients on non-valproate AEDs also exhibit carnitine deficiency, though mechanisms and consequences remain unclear.